Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of sucroferric oxyhydroxide (PA21) on serum calcification propensity in end-stage renal disease
2016-004789-24Phase 2Completed
- Sponsor
- Ordensklinikum Linz
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of iron sucrose in end-stage kidney disease (ESKD) (2 arms), sponsored by Ordensklinikum Linz. Primary endpoint: Change in T50 value. Started Jan 2017; status: completed.
02
Drugs
iron sucrose
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2016-004789-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004789-24.